Press Releases

24 Nov 2019The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 billion18 Nov 2019The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing16 Nov 2019The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing06 Nov 2019The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 201930 Oct 2019The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran24 Oct 2019The Medicines Company to Announce Third Quarter 2019 Financial Results on October 3004 Oct 2019The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference25 Sep 2019The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients25 Sep 2019The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients02 Sep 2019The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing01 Sep 2019The Medicines Company Statement on the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias26 Aug 2019The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran24 Jul 2019The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program17 Jul 2019The Medicines Company to Announce Second Quarter 2019 Financial Results on July 2425 Jun 2019The Medicines Company Announces Pricing of Public Offering of Common Stock24 Jun 2019The Medicines Company Announces Launch of Public Offering of Common Stock27 May 2019The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress18 May 2019New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years10 May 2019The Medicines Company to Host Investor Conference Call and Webcast During National Lipid Association’s 2019 Scientific Sessions07 May 2019The Medicines Company to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference25 Apr 2019The Medicines Company Reports First-Quarter 2019 Financial Results and Significant Progress with the Inclisiran Clinical Development Program18 Apr 2019The Medicines Company to Announce First Quarter 2019 Financial Results on April 2527 Feb 2019The Medicines Company Reports Fourth-Quarter and Full Year 2018 Business and Financial Results21 Feb 2019The Medicines Company Announces Upcoming Investor Conference Presentations20 Feb 2019The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 2707 Jan 2019The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com